Mass Spectrometry in Clinical Applications: 2014 Report

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Mass Spectrometry in Clinical Applications" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

For capacity, accuracy, and specificity of analysis, the use of mass spectrometry in clinical diagnostics and clinical research has grown dramatically in recent years. This Kalorama Information report, Mass Spectrometry for Clinical Applications: Market Analysis and End User Survey, looks at the growth of Mass Spec systems being used in diagnostics and other clinical applications this year.

A Detailed Examination of the Market Opportunity for MS in Clinical Applications

Prior to the explosion in the last several years, GC-MS, LC-MS, and LC-MS/MS were being used in diagnostics primarily only for newborn screening of metabolic diseases. Clinical research applications related mainly to pharmaceutical development. But the situation has changed dramatically as a number of applications have seen particularly rapid adoption in the last few years, including testing for microbial identification, steroids/ endocrinology, vitamin D, and therapeutic drug monitoring (TDM). A large range of diagnostic tests are being researched for both small molecules and proteins. Depending on the application, MS can have many advantages over the immunoassays typically used for most diagnostics. In some cases, there is simply no alternative testing method available.

• Clinical MS Market and Revenues Forecast
• Market Share of Clinical MS Systems by Product (MALDI-TOF, triple quad, QTRAP, ion trap, GCMS, Orbitrap & ion-Orbitrap, QTOF, Other)
• Clinical MS Market Share by Supplier
• Overview of Types of MS and Clinical Use
• Challenges
• Strategic Recommendations
• Company Profiles

INCLUDES: An End User Survey on Applications, Brand Ownership, Handling of Regulated Samples, Future Plans

A survey of 50 labs was conducted to get a better picture of the usage and trends with MS in clinical labs. Labs included in the survey are those running regulated patient samples for routine diagnostics, or unregulated patient samples for diagnostics/prognostics/ theranostics-oriented research. A wide breadth of labs was targeted in order to obtain a richer picture of the market. Results provided by the survey respondents include:

• Brands of MS Systems Used by Regulated/Not Regulated
• Types of MS Systems (triple quad, Q-trap, ion trap, MALDI TOF, GCMS, Q-TOF, Orbitrap, ion trap-Orbitrap, MALDI-TOF/TOF, triple TOF, isotope ratio MS, ICP-MS, N/D, Other) Used in Labs
• Labs' Certification/ Accreditation for Diagnostic MS
• Future Purchase Time Frame
• Brands of Systems Considered Most Appealing by Regulated/Not Regulated
• Most Important Trends in Clinical MS

Key Topics Covered:

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER TWO: INTRODUCTION

CHAPTER THREE: MARKET TRENDS

CHAPTER FOUR: CONSORTIA / ALLIANCES

CHAPTER FIVE: REVENUES FORECAST & COMPETITIVE ANALYSIS

CHAPTER SIX: END-USER SURVEY

CHAPTER SEVEN: CORPORATE PROFILES

CHAPTER EIGHT: CHALLENGES

CHAPTER NINE: STRATEGIC RECOMMENDATIONS

Companies Mentioned:

• AB Sciex (DANAHER CORPORATION)
• Agilent Technologies
• Bruker Corporation
• Perkin Elmer
• Thermo Fisher
• Waters Corporation

For more information visit http://www.researchandmarkets.com/research/xb4jvb/mass_spectrometry

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net